Explore how epigenetics is transforming lung cancer diagnostics, offering earlier detection, greater precision, and renewed hope. Read how Volition's technology is lighting the way forward in #LungCancer detection: tinyurl.com/ydj5deyf #LungCancerAwareness #Epigenetics

Nu.Q® Discover is a valuable research tool to support your drug discovery and development need, from target identification to validation, in clinical studies. Find out more: tinyurl.com/495heavk

Some Nu.Q® Vet Cancer Test questions we get asked often, answered by Dr. Lisa Lippman! Find out more on our website: tinyurl.com/3vkenb6w

Meet our Chief Operating Officer, Gaetan! Gaetan has been with Volition for 10+ years, expanding operations not only in Europe, but also in the U.S. Find out more: tinyurl.com/4fd7az8y

On-Demand Webinar: Early Detection with Canine Cancer Screening 🐶 Explore the challenges and unmet needs in diagnosing canine cancer with insights from Dr. Sue Ettinger (aka Sue Ettinger DVM) — a leading expert in veterinary oncology. This RACE-approved webinar covers: ✅

32% of adults in Northern Ireland say they confidently know what sepsis is. A new YouGov survey commissioned by Sepsis Research FEAT reveals widespread gaps in awareness — especially among younger adults and men.

This Intensive Care Week, we’re shining a light on the people, progress, and possibilities behind #criticalcare. We sat down with our Chief Medical Officer, Dr. Andrew Retter, to discuss the evolution of intensive care, from the pressures of the pandemic to the promise of AI and

Volition announces two oral presentations at the Asian Meeting of Animal Medicine Specialties, highlighting advances in veterinary diagnostics. Find out more: tinyurl.com/3w2tjjy2

New MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure. Learn more in our press release: tinyurl.com/3nmhvdc6

Join our poster presentation at #ISTH2025 today: ⌚1:45 PM - 2:45 PM EDT Poster number: PB1615

VolitionRx — Nu.Q advances in lung cancer management. $VNRX #NYSE Volition edisongroup.com/research/nu-q-…

NEWS: Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes Read the press release: tinyurl.com/2bwf3fcm

Curious about utilising the Nu.Q® Vet Cancer Test in your practice? Join our free webinar for practical tips, case studies, and more! 📅 July 16 ⌚ 8pm BST/3pm ET/12 noon PT 🔗 Register here: tinyurl.com/nhabdze6 #VetWebinar #VeterinaryMedicine #CanineCancer

In our new paper, published in Journal of Biological Chemistry, we aim to inform about our Nu.Q® immunoassays, which can be applied at all stages of drug development, from cell models to patient blood samples. Download: tinyurl.com/yc69thh3

Curious about utilising the Nu.Q® Vet Cancer Test in your practice? Join our free webinar TOMORROW for practical tips, case studies, and more! 📅 July 16 ⌚ 8pm BST/3pm ET/12 noon PT 🔗 Register here: tinyurl.com/nhabdze6 #VetWebinar #VeterinaryMedicine #CanineCancer

NEWS: Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation. Read more in our press release: tinyurl.com/yck5rpmn

We can't wait to meet you at #AVMA2025 this weekend! Stop by booth 1441 to hear the latest updates on Nu.Q® Vet, our simple blood test to aid early detection of cancer in dogs. #VetMed #CanineCancer

Volition colleagues installed the IDS i10 machine at National Taiwan University this week. This marks a significant milestone in the validation study assessing the potential value of Nu.Q® assays in differentiating lung cancer and non-malignant nodules, for use as a

New paper published in @PlosOne: Quantification of H3.1-nucleosomes using a chemiluminescent immunoassay: A reliable method for neutrophil extracellular trap detection Download from our website: tinyurl.com/3jcb4pbb

We have just announced our Q2 2025 financial results and business update. Join our conference call tomorrow at 8:30 a.m. ET to find out more. Read our press release: tinyurl.com/2rkv4a83